Anisomycin |  | | SYNONYMS | 2-(p-Methoxybenzyl)-3,4-pyrrolidinediol-3-acetate | | | | PRODUCT LINE | Natural Products / Antibiotics | | | | PRODUCT FAMILIES | Antibiotics - Other Signal Transduction Pathway Modulators | | | | | Ordering Information | | | Product Numbers | Format | Size | Unit Price | Quantity | | | ALX-380-051-M010 |
|
10 mg | | | | | ALX-380-051-M050 |
|
50 mg | | | | | ALX-380-051-M100 |
|
100 mg | | | | | | |
| | | Product Specification | | |
| FORMULA: | C14H19NO4 | | | | | |
| MW: | 265.3 | | | | | |
| CAS NUMBER: | 22862-76-6 | | | | | |
| MERCK INDEX: | 14: 670 | | | | | |
| RTECS: | BZ9800000 | | | | | |
| SOURCE/HOST: | Isolated from Streptomyces griseolus. | | | | | |
| PURITY: | ≥98% (HPLC) | | | | | |
| APPEARANCE: | White crystalline solid. | | | | | |
| SOLUBILITY: | Soluble in DMSO (25mg/ml), 100% ethanol, methanol or ethyl acetate (10mg/ml). | | | | | |
| SHIPPING: | AMBIENT | | | | | |
| LONG TERM STORAGE: | -20°C | | | | | |
| HAZARD: | TOXIC. | | | | | | Product Description | Antibiotic. Activator of p38 and MAP kinases. Synergistic with growth factors and phorbol esters to superinduce cFos and cJun, by acting as a potent signalling agonist. Induces apoptosis in the human monoblastoid cell line. Used in the eradication of bean mildew. Inhibits other pathogenic fungi in plants. |
| | | Product Specific Literature References | Anisomycin, a new anti-protozoan antibiotic: B. A. Sobin & F. W. Tanner; J. Am. Chem. Soc. 76, 4053 (1954)
DNA fragmentation and cytolysis in U937 cells treated with diphtheria toxin or other inhibitors of protein synthesis: S.K. Kochi & R.J. Collier; Exp. Cell. Res. 208, 296 (1993) Abstract
The stress-activated protein kinase subfamily of c-Jun kinases: J.M. Kyriakis, et al.; Nature 369, 156 (1994) Abstract
Role of SAPK/ERK kinase-1 in the stress-activated pathway regulating transcription factor c-Jun: I. Sanchez, et al.; Nature 372, 794 (1994) Abstract
Anisomycin and rapamycin define an area upstream of p70/85S6k containing a bifurcation to histone H3-HMG-like protein phosphorylation and c-fos-c-jun induction: E. Kardalinou, et al.; Mol. Cell. Biol. 14, 1066 (1994) Abstract
Protein synthesis inhibitor phase shifts vasopressin rhythms in long- term suprachiasmatic cultures: K. Shinohara & T. Oka; NeuroReport 5, 2201 (1994) Abstract
Anisomycin selectively desensitizes signalling components involved in stress kinase activation and fos and jun induction: C.A. Hazzalin, et al.; Mol Cell Biol 18, 1844 (1998) Abstract
Anisomycin treatment paradigm affects duration of long-term potentiation in slices of the amygdala: P. Okulski, et al.; Neuroscience 114, 1 (2002) Abstract
Downregulation of Ski and SnoN co-repressors by anisomycin: A. Vazquez-Macias, et al.; FEBS Lett. 579, 3701 (2005) Abstract
Anisomycin and the reconsolidation hypothesis: J.W. Rudy, et al.; Learn. Mem. 13, 1 (2006), Review Abstract
A chemical screen identifies anisomycin as an anoikis sensitizer that functions by decreasing FLIP protein synthesis: I.A. Mawji, et al.; Cancer Res. 67, 8307 (2007) Abstract
Anisomycin abrogates repression of protooncogene c-fos transcription in E1A + cHa-ras-transformed cells through activation of MEK/ERK kinase cascade: A. N. Kukushkin, et al.; J. Cell. Biochem. 103, 1005 (2008) Abstract |
| | | | | RELATED PRODUCT GROUPS | Signal Transduction > MAP Kinase Pathways > MAPK Pathway Activators / Signal Transduction > MAP Kinase Pathways > JNK [SAPK1] / Related Products / Natural Products / Antibiotics > Antibiotics > Antibiotics - Apoptosis Inducers & Inhibitors | | | | | |
